SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

XTX602

XLO·Xilio Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / IND-enabling
Time to market
IND filing planned for Q4 2027; if approved, earliest commercialization would be many years away, contingent on successful Phase 1, Phase 2, and Phase 3 trials.
Why 2/10
XTX602 is a preclinical candidate with no hard binary catalyst in the next ~12 months; the next scheduled milestone is an IND filing in Q4 2027, roughly a year away, and XTX602 is not Xilio's lead asset (that is XTX501, whose Phase 1 data are due Q4 2027).
Actionable Insight NEUTRAL

The next catalyst for XTX602 is an IND filing planned for Q4 2027, which is roughly 12 months away. The nearer-term drivers for XLO stock are the Gilead option decision on XTX301 (H1 2027) and initial Phase 1 data for lead asset XTX501 (Q4 2027). Until XTX602 enters the clinic, investors will value XLO primarily on XTX501 progress and partnership outcomes.

Price Chart

Loading chart...

Executive Summary

XTX602 is a preclinical-stage masked immuno-oncology candidate from Xilio Therapeutics (Nasdaq: XLO), a ~$58M market-cap biotech. The drug's mechanism has not been publicly specified, but Xilio's pipeline uses a \"masked\" platform designed to activate immune therapies only inside tumors. XTX602 is an early-stage pipeline program; the company plans to file an IND in Q4 2027, roughly 12 months away. Xilio's lead asset is XTX501 (Phase 1/2, PD-1/masked IL-2 bispecific), and its most advanced partnered asset is XTX301 (licensed to Gilead). With no approved products, the stock trades entirely on pipeline progress and partnership outcomes.

How It Works

Xilio develops \"masked\" immunotherapies that are designed to remain inactive until they reach the tumor environment, potentially reducing side effects compared to traditional immune-stimulating drugs. XTX602 is a preclinical-stage candidate from this platform, though its specific molecular target and mechanism have not been publicly detailed. Based on Xilio's pipeline descriptions, it is likely a multi-specific, masked T cell engager (an engineered antibody that directs immune T cells to attack cancer cells) targeting tumor-associated antigens.

Trial Status

XTX602 is in IND-enabling studies. Xilio's Q3 2026 earnings press release listed XTX602 as an advancing pipeline program with an IND submission targeted for Q4 2027. No clinical trials have been initiated.

The Two-Sided Case

▲ Bull Case4
Xilio's cash position of $122.2M provides runway into Q1 2028, giving XTX602 ample time to reach the clinic without near-term financing pressure.
The company's masked immuno-oncology platform has been validated by a Gilead partnership for XTX301 (tumor-activated IL-12), lending credibility to platform derivatives like XTX602.
Analyst consensus is bullish (5 Buy/Strong Buy, 1 Hold, 0 Sell) with a mean price target of $18, implying 122.9% upside from the $8.075 close.
Raymond James initiated coverage with an Outperform rating in October 2026, adding fresh analyst attention.
▼ Bear Case4
XTX602 is preclinical/IND-enabling, with an IND filing not expected until Q4 2027; it may never reach the clinic or fail in development.
Xilio has no approved products and its only revenue is from collaboration agreements ($10.0M in Q3 2026, down 47.6% YoY). The stock has a tiny market cap (~$58M) and is a single-miss away from distress.
The company executed a 1-for-14 reverse stock split in March 2026, signaling prior share-price distress, and further dilution from Series C warrant exercises (up to $36.2M) looms.
Exact mechanism and target of XTX602 have not been publicly disclosed; the program is at a very early, high-risk stage with no efficacy or safety data.

Upcoming Catalysts

  • IND filing for XTX602 targeted for Q4 2027
  • Gilead option decision on XTX301 (tumor-activated IL-12) expected H1 2027
  • Initial Phase 1 data for lead asset XTX501 expected Q4 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xilio Therapeutics, Inc. PRESS-RELEASE XLO ·Originating report

Sources · 5

Hover a chip for the title
1 morningstar.com2 rttnews.com3 marketscreener.com4 natlawreview.com5 wboc.com